Daesung Microbiological Labs대성미생물
036480 · KOSDAQ · ₩036480 · 대성미생물
₩5,490▼ ₩20 (0.36%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩26B | ₩24B | ₩26B | ₩26B | ₩24B |
| Cost of sales | ₩20B | ₩20B | ₩21B | ₩21B | ₩18B |
| Gross profit | ₩6.4B | ₩4.1B | ₩4.8B | ₩4.8B | ₩5.7B |
| Operating income | ₩714M | −₩1.6B | −₩689M | −₩328M | ₩337M |
| Net income | ₩598M | −₩1.8B | −₩680M | ₩1.7B | ₩866M |
| Net income to shareholders | ₩598M | −₩1.8B | −₩680M | ₩1.7B | ₩866M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩58B | ₩58B | ₩64B | ₩65B | ₩63B |
| Current assets | ₩25B | ₩24B | ₩29B | ₩29B | ₩24B |
| Cash and equivalents | ₩3.4B | ₩3.6B | ₩4.4B | ₩3.9B | ₩4.4B |
| Total liabilities | ₩23B | ₩23B | ₩27B | ₩26B | ₩26B |
| Current liabilities | ₩8.5B | ₩4.5B | ₩10B | ₩11B | ₩5.3B |
| Borrowings | ₩15B | ₩19B | ₩22B | ₩22B | ₩22B |
| Total equity | ₩35B | ₩35B | ₩37B | ₩39B | ₩37B |
| Shareholders' equity | ₩35B | ₩35B | ₩37B | ₩39B | ₩37B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | ₩1.4B | ₩2.1B | −₩1.2B | ₩1.2B | ₩2.2B |
| Free cash flow | ₩1.4B | ₩2.1B | −₩1.2B | ₩1.2B | ₩2.2B |
Consolidated where available. Amounts in won.
Also known as: Daesung Microbiological Labs / 대성미생물 / 036480 / KRX:036480
Source: KRX statistical information